A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close behind
Eli Lilly $LLY has scored the fast FDA approval it was gunning for when the pharma giant plunked down $8 billion to acquire Loxo …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
